Analysts See $0.45 EPS for Chatham Lodging Trust (CLDT), 5 Analysts Bullish Evoke Pharma (EVOK)

May 8, 2017 - By Henry Gaston

Analysts expect Chatham Lodging Trust (NYSE:CLDT) to report $0.45 EPS on May, 9 before the open.They anticipate $0.01 EPS change or 2.17% from last quarter’s $0.46 EPS. CLDT’s profit would be $17.45 million giving it 10.82 P/E if the $0.45 EPS is correct. After having $0.44 EPS previously, Chatham Lodging Trust’s analysts see 2.27% EPS growth. The stock increased 0.93% or $0.18 on May 5, reaching $19.48. About shares traded. Chatham Lodging Trust (NYSE:CLDT) has risen 0.57% since September 29, 2016 and is uptrending. It has underperformed by 10.97% the S&P500.

Among 7 analysts covering Evoke Pharma (NASDAQ:EVOK), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Evoke Pharma had 12 analyst reports since August 20, 2015 according to SRatingsIntel. The company was upgraded on Thursday, January 5 by Rodman & Renshaw. The stock has “Neutral” rating by Rodman & Renshaw on Monday, July 18. Rodman & Renshaw initiated the stock with “Buy” rating in Friday, October 2 report. Ascendiant Capital maintained Evoke Pharma Inc (NASDAQ:EVOK) rating on Monday, March 14. Ascendiant Capital has “Buy” rating and $12 target. The stock of Evoke Pharma Inc (NASDAQ:EVOK) has “Buy” rating given on Thursday, October 1 by H.C. Wainwright. The firm has “Buy” rating by Brean Capital given on Thursday, August 20. The company was downgraded on Monday, July 18 by Brean Capital. The firm has “Neutral” rating given on Friday, December 23 by Rodman & Renshaw. Northland Capital initiated the stock with “Outperform” rating in Wednesday, March 16 report. The stock has “Buy” rating by Laidlaw on Monday, January 30. See Evoke Pharma Inc (NASDAQ:EVOK) latest ratings:

30/01/2017 Broker: Laidlaw Old Rating: Neutral New Rating: Buy New Target: $8 Upgrade
05/01/2017 Broker: Rodman & Renshaw Old Rating: Neutral New Rating: Buy Old Target: $2.50 New Target: $6.00 Upgrade
23/12/2016 Broker: Rodman & Renshaw Rating: Neutral Old Target: $2 New Target: $2.50 Maintain

Chatham Lodging Trust is a real estate investment trust. The company has market cap of $755.42 million. The Firm invests primarily in upscale extended-stay and premium-branded select-service hotels. It has a 24.1 P/E ratio. All of the Company’s assets are held by, and all of its activities are conducted through Chatham Lodging, L.P. .

Among 7 analysts covering Chatham Lodging (NYSE:CLDT), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Chatham Lodging had 12 analyst reports since August 11, 2015 according to SRatingsIntel. As per Thursday, August 4, the company rating was downgraded by FBR Capital. The stock of Chatham Lodging Trust (NYSE:CLDT) earned “Outperform” rating by FBR Capital on Friday, November 20. Barclays Capital downgraded the shares of CLDT in report on Thursday, August 4 to “Equal-Weight” rating. The stock of Chatham Lodging Trust (NYSE:CLDT) has “Buy” rating given on Friday, January 8 by BB&T Capital. The firm has “Mkt Perform” rating given on Monday, November 7 by FBR Capital. The firm earned “Overweight” rating on Wednesday, March 9 by Barclays Capital. FBR Capital maintained it with “Mkt Perform” rating and $22 target in Tuesday, October 11 report. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, March 29. The firm earned “Hold” rating on Wednesday, October 12 by Cantor Fitzgerald. JMP Securities maintained the stock with “Market Outperform” rating in Tuesday, August 11 report.

Investors sentiment decreased to 1.16 in Q4 2016. Its down 0.24, from 1.4 in 2016Q3. It fall, as 13 investors sold Chatham Lodging Trust shares while 43 reduced holdings. 20 funds opened positions while 45 raised stakes. 32.26 million shares or 0.98% less from 32.58 million shares in 2016Q3 were reported. Gam Hldg Ag reported 0% stake. Moreover, Jennison Ltd Liability Corp has 0.06% invested in Chatham Lodging Trust (NYSE:CLDT). State Of New Jersey Common Pension Fund D stated it has 0.02% of its portfolio in Chatham Lodging Trust (NYSE:CLDT). Mutual Of America Capital Mgmt Llc invested in 191,246 shares or 0.07% of the stock. Omers Administration Corp holds 0.01% or 20,200 shares. Clean Yield Gru holds 15,000 shares. Crow Point Prns Limited Liability has 1.25 million shares. Dimensional Fund Lp invested 0% of its portfolio in Chatham Lodging Trust (NYSE:CLDT). Parametric Associates Ltd Co reported 45,531 shares. Aqr Capital Mgmt Ltd Llc stated it has 0% of its portfolio in Chatham Lodging Trust (NYSE:CLDT). Tower Research Capital Ltd Liability (Trc) has invested 0% in Chatham Lodging Trust (NYSE:CLDT). Susquehanna Int Group Llp invested in 88,470 shares. D E Shaw And stated it has 0% in Chatham Lodging Trust (NYSE:CLDT). Prudential invested in 284,903 shares. Forward Mngmt Ltd Liability holds 2.04M shares or 2.93% of its portfolio.

The stock increased 4.09% or $0.11 on May 5, reaching $2.8. About shares traded. Evoke Pharma Inc (NASDAQ:EVOK) has risen 27.85% since September 29, 2016 and is uptrending. It has outperformed by 16.32% the S&P500.

Since February 22, 2017, it had 1 buy, and 0 insider sales for $1.31 million activity. 450,000 Evoke Pharma Inc (NASDAQ:EVOK) shares with value of $1.31M were bought by WIDDER KENNETH J.

Evoke Pharma, Inc. is a specialty pharmaceutical company. The company has market cap of $44.85 million. The Firm is focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. It currently has negative earnings. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.